Book chapter
Complications of Intravesical Therapy
Complications of Urologic Surgery and Practice, pp.455-476
Informa Healthcare, 1
2007
DOI: 10.3109/9781420013955-33
Abstract
The scientific rationale behind the use of intravesical chemotherapy is to introduce a cytotoxic drug at relatively high concentration directly to the tumor cells while minimizing systemic exposure. Two general formats have been widely used. Thiotepa is a polyfunctional alkylating agent related chemically and pharmacologically to nitrogen mustard. It results in DNA cross-linkage thereby interfering with protein synthesis to exert its cytotoxic effect. The anthracycline family includes doxorubicin as well as all its derivatives including epirubicin, pirarubicin, and valrubicin. All of these have been tested as intravesical agents with doxorubicin tested the most, followed by epirubicin and valrubicin. Intravesical therapy with cytotoxic chemotherapy or immunotherapeutics share several common features of inducing local toxicity in the form of chemical or inflammatory cystitis. In the chemotherapy group this is more prevalent with known vesicant agents and during longterm therapy with high drug concentrations.
Details
- Title: Subtitle
- Complications of Intravesical Therapy
- Creators
- Michael A O’DonnellJosé L Maymí
- Contributors
- Kevin R Loughlin (Editor)
- Resource Type
- Book chapter
- Publication Details
- Complications of Urologic Surgery and Practice, pp.455-476
- Edition
- 1
- Publisher
- Informa Healthcare
- DOI
- 10.3109/9781420013955-33
- Alternative title
- Complications of Intravesical Therapy
- Language
- English
- Date published
- 2007
- Academic Unit
- Urology
- Record Identifier
- 9984320062302771
Metrics
34 Record Views